Stem Cell Clinic

Mayo Clinic Discovery Leads to FDA Approval for Stem Cell Trial for Heart Failure Patients

By Stem Cell Clinic

Dennis Douda (@ddouda) published a blog post January 17th, 2014

Mayo Clinic Discovery Leads to FDA Approval for Stem Cell Trial for Heart Failure Patients

U.S. FDA Approves Phase III Cardiopoietic Stem Cell Trial for Heart Failure Patients Based on a Mayo Discovery

Cardio3 BioSciences, an international Mayo Clinic collaborator, has received FDA approval for a phase III pivotal clinical trial of its stem cell therapy.The trial will test the Mayo Clinic discovery of cardiopoietic (cardiogenically-instructed) stem cells designed to improve heart health in people suffering from heart failure.The multisite U.S. trial, called CHART-2, will aim to recruit 240 patients with chronic advanced symptomatic heart failure. Cardio3 BioSciences is a bioscience company in Mont-Saint-Guibert, Belgium.

"Regenerative medicine is poised to transformthe way we treat patients," says Andre Terzic, M.D., Ph.D., director of the Mayo Clinic Center for Regenerative Medicine. Watch the video below to see how stem cells are being used to treat people with heart failure.

Journalists: Video b-roll of today's news conference, plussound bites with Dr. Terzic and Christian Homsy, M.D., CEO of Cardio3 BioSciences, areavailable in the downloads. The video pkg. is also available in the downloads in MOV format.

Cardio3 Biosciencescardiopoetic Dr. Andre Terzic Dr Terzic Heart heart diseaseregenerative medicine stem cells

Follow this link:
Mayo Clinic Discovery Leads to FDA Approval for Stem Cell Trial for Heart Failure Patients

Bioquark Inc. Appoints Dr. Joel I. Osorio MD, Specialist in Functional Anti-Aging Regenerative and Stem Cell Medicine …

By Uncategorized

Philadelphia, PA (PRWEB) January 23, 2014

Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of combinatorial biologics for regeneration and disease reversion in human organs and tissues, today announces the appointment of Dr. Joel I. Osorio MD, as VP of International Clinical Development.

We are honored to have someone with Dr. Osorios experience join us as we execute on a globalized clinical strategy, said Ira S. Pastor, CEO, Bioquark Inc. His broad clinical experience in functional anti-aging regenerative and stem cell based medicine make him a very valuable addition to the Bioquark team.

Dr. Osorio brings over 9 years of experience in medical practice, both in the private practice and public medical settings. Currently the medical director of the medical spa Bamboo Rejuvenecimiento Facial y Coporal (http://www.bamboobelleza.com), Dr. Osorio has served in capacities in both private and public practice, as a hospital staff physician, and as emergency health services coordinator for a variety of private and public institutions throughout Mexico. He earned MD degrees at both Westhill University and the National Autonomous University of Mexico as a medical surgeon, has diplomas in aesthetic medicine from the Autonomous University of Guadalajara, is an Advance Fellow by the American Board of Anti-Aging and Regenerative Medicine (http://www.a4m.com/joel-osorio-bamboo-rejuvenecimiento-facial-y-corporal-naucalpan-estado-de-mxico.html), is a visiting scholar at University of North Carolina at Chapel Hill in dermatology, a fellow in stem cell medicine by the American Academy of Anti-Aging Medicine and University of South Florida, and currently is completing additional masters work in metabolic and nutrition sciences at University of South Florida. Dr. Osorio is also a member of the round table of ReGeNeRaTe Laboratories Mexico Committee (a DNAge-Lab Company), and has been actively working in the applied stem cell field since 2007. In 2011, Dr. Osorio became a member of the International Cellular Medicine Society, is a PRP certified practitioner in aesthetic and regenerative fields, and from 2009 to 2012 managed the blood bank at Ruben Lenero public hospital. Dr. Osorio frequently appears on Mexican national television programs and interviews regularly as a speaker on the topic of anti-aging (http://www.youtube.com/watch?v=Z4SvkBTS-P0) as well as contributes in various magazines and periodicals on anti-aging related subjects.

I am very excited about the candidates being developed at Bioquark and their very novel approach to human regeneration and disease reversion, as well as the broader biological programs focused on anti-aging," said Dr. Osorio. "I'm pleased to be joining the team and am looking forward to playing a more active role in this truly transformational platform."

About Bioquark, Inc. Bioquark Inc. (http://www.bioquark.com) is focused on the development of biologic based products that have the ability to alter the regulatory state of human tissues and organs, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

See original here:
Bioquark Inc. Appoints Dr. Joel I. Osorio MD, Specialist in Functional Anti-Aging Regenerative and Stem Cell Medicine ...

Scientists find estrogen promotes blood-forming stem cell function

By Uncategorized

Jan. 22, 2014 Scientists have known for years that stem cells in male and female sexual organs are regulated differently by their respective hormones. In a surprising discovery, researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) and Baylor College of Medicine have found that stem cells in the blood-forming system -- which is similar in both sexes -- also are regulated differently by hormones, with estrogen proving to be an especially prolific promoter of stem cell self-renewal.

The research, published in Nature, raises several intriguing possibilities for further investigation that might lead to improved treatments for blood cancers and increased safety and effectiveness of chemotherapy.

Before the finding, blood-forming stem cells were thought to be regulated similarly in both males and females, according to the paper's senior author, Dr. Sean Morrison, Director of CRI, Professor of Pediatrics, and the Mary McDermott Cook Chair in Pediatric Genetics at UT Southwestern Medical Center.

However, while working in Dr. Morrison's laboratory as postdoctoral fellows, Dr. Daisuke Nakada, the first and co-corresponding author of the study, and Dr. Hideyuki Oguro discovered that blood-forming stem cells divide more frequently in females than in males due to higher estrogen levels. The research, conducted using mice, demonstrated that the activity of blood-forming stem cells was regulated by systemic hormonal signals in addition to being regulated by local changes within the blood-forming system.

"This discovery explains how red blood cell production is augmented during pregnancy," said Dr. Morrison. "In female mice, estrogen increases the proliferation of blood-forming stem cells in preparation for pregnancy. Elevated estrogen levels that are sustained during pregnancy induce stem cell mobilization and red cell production in the spleen, which serves as a reserve site for additional red blood cell production."

The study involved treating male and female mice over a period of several days with amounts of estrogen needed to achieve a level consistent with pregnancy. When an estrogen receptor that is present within blood-forming stem cells was deleted from those cells, they were no longer able to respond to estrogen, nor were they able to increase red blood cell production. The results demonstrate that estrogen acts directly on the stem cells to increase their proliferation and the number of red blood cells they generate.

"If estrogen has the same effect on stem cells in humans as in mice, then this effect raises a number of possibilities that could change the way we treat people with diseases of blood cell-formation," said Dr. Morrison. "Can we promote regeneration in the blood-forming system by administering estrogen? Can we reduce the toxicity of chemotherapy to the blood-forming system by taking into account estrogen levels in female patients? Does estrogen promote the growth of some blood cancers? There are numerous clinical opportunities to pursue."

Continued here:
Scientists find estrogen promotes blood-forming stem cell function

stem cell therapy treatment for global developmental delay by dr alok sharma, mumbai, india – Video

By Uncategorized


stem cell therapy treatment for global developmental delay by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for ______ by dr alok sharma, mumbai, india. Stem Cell Therapy done date 17/12/2013 After S...

By: Neurogen Brain and Spine Institute

Link:
stem cell therapy treatment for global developmental delay by dr alok sharma, mumbai, india - Video

National Regenerative Medical Practice – Stem Cell Therapy …

By Stem Cell Medicine

It's been nothing but 100% improvement.It just continues to get better.Ive been avoiding doing stairways and I have to be real careful climbing in and out of equipment. I find myself being a lot more relaxed, not having the problems, not having the pain. I don't have the swelling in my knees that I used to have and it hasnt been waking me up at night. View my video testimonial here My name is Susan and Im 62 year old I just finished having my second PRP treatment and Im very, very happy with the results I can do all kinds of things I wasn't able to do beforeI believe my knee will continue to get better as the cartilage grows. Thank you! View my video testimonial here

Many thanks to the Stem MD team for giving me the use of my hands back, pain free! Professional, courteous and compassionate, describes this team of caring people. To anyone considering this procedure, I say you will be amazed and thankful at the results.

Lenita Brewer Ansonia, Ohio

Thank you for giving my life and health back. The PRP treatment worked wonders and helped alleviate the pain. I highly recommend the anti-inflammatory diet, Dr. Purita suggested. My body noticed the difference and I lost 35 pounds. I can finally be active again!

Jennica Califf Coconut Creek, Florida

I thought there was no hope for my chronic back pain. I am so thankful I found out about Dr. Purita and stem cells. I have had back pain for over 5 years, debilitating me to do everyday things. Today my pain has gone down 50%. I tell all my friends and family and wish everyone knew about this wonderful treatment. Thank you so much Dr. Purita

It has been 3 months since my mothers procedure to her knees. Now, my mom climbs into the van without any help, before we had to pull her up and assist her. She does not take painkillers anymore, even her recurring bladder infection and Diabetes is well controlled. All my friends and colleagues are super amazed every time I show them a video of my mom dancing. Thank you so much what you have done for my mom it is truly wonderful and I am forever indebted to you.

Malou Aragon-De Veyra Philippines

I came to Dr. Purita on the advice of a friend when I expressed trepidations about cortisone shots or the possibility no matter how remote of a joint replacement. I was a wrestler in high school and college, and this had done no good for my kneed as I aged. I had no expectations, only hope that somehow my knees could be made less fragile by the stem cell therapy my friend described. I had gotten to the point where any down stairs journey or stepping down off a van or public bus was excruciating, to the point that I usually made an exclamation that wasn't fit for public utterance every time I stepped off a bus or a van. My expectations were neutral at best. I had no idea as to how this stem cell therapy would impact my general health whatsoever. I can say without hesitation that the results have been beyond what I could have hoped. My knees are now cooperative to the point that sometimes I take the stairs down just because I can. I have resumed walking the stairs up and down at work, and I can say that I really don't think about anything I want to do where my kneed are involved. I am not quite where I was when I was 20, but 35 is a real thought, my flexibility and agility are restored to a level I could not have imagined. As an additional part of the procedure Dr. Purita also injected stem cell into my left hand, which has been diagnosed with some arthritis. The results are less instantaneously spectacular, but the had continues to improve. I no longer sit in my office while my hand burns with joint pain, my movement and most of my strength are improving daily, and I have a feeling that within a month or so I will have the same level of improvement I have experiences with my knees. Many thanks to the friend who recommended the trip to Dr. Purita's office, and to Dr. Purita and his staff who have put thoughts of joint replacement and the mad merry-go-round of cortisone shots far in the past for me.

Mark Burns Hypoluxo, Florida

Continued here:
National Regenerative Medical Practice - Stem Cell Therapy ...

Number of cancer stem cells might not predict outcome in HPV-related oral cancers

By Stem Cell Medical Center

PUBLIC RELEASE DATE:

22-Jan-2014

Contact: Amanda J. Harper amanda.harper2@osumc.edu 614-685-5420 Ohio State University Wexner Medical Center

COLUMBUS, Ohio New research from The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) suggests that it may be the quality of cancer stem cells rather than their quantity that leads to better survival in certain patients with oral cancer.

The researchers investigated cancer stem cell numbers in oral cancers associated with human papillomavirus (HPV) and in oral cancers not associated with the virus. Typically, patients with HPV-positive oral cancer respond better to therapy and have a more promising prognosis than patients with HPV-negative tumors. The latter are usually associated with tobacco and alcohol use.

The OSUCCC James team's findings, published in the journal Cancer, suggest that relying on the number of cancer stem cells in a tumor might inaccurately estimate the potential for the tumor's recurrence or progression.

"We show that high levels of cancer stem cells are not necessarily associated with a worse prognosis in head and neck cancer, a finding that could have far-reaching implications for patient care," says principal investigator Quintin Pan, PhD, associate professor of otolaryngology and scientist with the OSUCCC James Experimental Therapeutics Program.

Head and neck cancer is the sixth most common cancer worldwide, with an estimated 600,000 cases diagnosed annually. Although the disease is often linked to alcohol and tobacco use, cancer-causing types of HPV are a major risk factor for the malignancy, and cases of HPV-associated oral cancers have tripled in the past 30 years.

Cancer stem cells make up only a small percent of the malignant cells within a tumor. When these cells divide, they can produce either more cancer stem cells or the nondividing malignant cells that constitute the bulk of a tumor.

Research has shown that cancer stem cells are highly resistant to chemotherapy and radiation and those cancer stem cells that survive treatment cause tumor recurrence. For these reasons, it is thought that tumors with high numbers of cancer stem cells are more likely to recur.

View post:
Number of cancer stem cells might not predict outcome in HPV-related oral cancers

January Tipsheet From Cedars-Sinai Medical Center

By Stem Cell Medical Center

Contact Information

Available for logged-in reporters only

World Health Organization Study: Atrial Fibrillation is a Growing Global Health Concern Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the conditions worldwide prevalence, death rates and societal costs. The World Health Organization data analysis, led by Sumeet Chugh, MD, shows that 33.5 million people worldwide or .5% of the worlds population have the condition. CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Clinical Trial Aims to Identify Why Some Breast Cancer Patients Are at High Risk for Post-Treatment Fatigue Although the prevalence and impact of cancer-related fatigue has been well established, very little is known about its predictors, mechanisms for development, and persistence post-treatment. A new research study at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in partnership with UCLA, is aimed at identifying breast cancer patients most susceptible to post-treatment fatigue by measuring biological, behavioral and social risk factors. CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org

Rose Parade Offers Kidney Donor Opportunity to Honor Her Brother-In-Law Terie Cota, an elementary school administrator from Santa Maria, Calif., describes herself as an average 56-year-old woman. She has been married 34 years, is the mother of four sons and grandmother of two little girls. But there is nothing average about Terie Cota because she chose to do something few others would think to do: She donated one of her healthy kidneys to a total stranger. CONTACT: Laura Coverson, 310-423-5215; Email laura.coverson@cshs.org

Cedars-Sinai Researchers Target Cancer Stem Cells in Malignant Brain Tumors Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute identified immune system targets on cancer stem cells cells from which malignant brain tumors are believed to originate and regenerate and created an experimental vaccine to attack them. Results of laboratory and animal studies are published in the online edition of Stem Cells Translational Medicine, and will appear in the March 2014 print edition. CONTACT: Sandy Van, 808-526-1708; Email sandy@prpacific.com

Physicians Now Analyze Mothers Milk to Determine if Premature Babies Are Getting Correct Dosages of Nutrients Physicians in the Neonatal Intensive Care Unit in the Maxine Dunitz Childrens Health Center launched a pilot study in which mothers breast milk is analyzed to determine whether premature infants are receiving the correct amounts of nutrients they need to thrive. The study could lead to a new innovation in personalized medicine: individually optimized nutrition for the smallest patients. CONTACT: Soshea Leibler, 213-215-8000; Email Soshea.leibler@cshs.org

Researchers Identify Key Proteins Responsible for Electrical Communication in the Heart Cedars-Sinai Heart Institute researchers have found that six proteins five more than previously thought are responsible for cell-to-cell communication that regulates the heart and plays a role in limiting the size of heart attacks and strokes. The smallest of these proteins directs the largest in performing its role of coordinating billions of heart cells during each heartbeat. Together, the proteins synchronize the beating heart, the researchers determined. CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Research Advancements Made in Diabetes-Induced Blindness Investigators at the Cedars-Sinai Regenerative Medicine Institute have identified new molecular abnormalities in the diabetic cornea that could contribute to eye problems in affected patients. With this new knowledge, investigators aim to accelerate the process of healing and repair in damaged corneas to ultimately reverse the effects of diabetes-induced eye complications. CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org

Research for Her TM, an Online Clinical Research Registry, Honored With Distinguished National Award Research for HerTM , a Cedars-Sinai online medical research database aimed at increasing womens participation in clinical studies, received the 2013 Award for Excellence from the Health Improvement Institute for its user-friendly electronic consent form. The Research for Her registry allows women to register for potential participation in clinical trials through an online, verified consent process that is just two pages long and written in nontechnical, easy-to-understand language. In comparison, a typical clinical trial consent form, even for low-risk clinical trials, is a printed document ranging from eight to 15 pages and includes complex medical and legal terminology. CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org

The rest is here:
January Tipsheet From Cedars-Sinai Medical Center

FASEB announces 2014 Science Research Conference: Skeletal Muscle Satellite and Stem Cells

By Stem Cell Clinic

PUBLIC RELEASE DATE:

22-Jan-2014

Contact: Robin Crawford src@faseb.org 301-634-7010 Federation of American Societies for Experimental Biology

Bethesda, MD This 2014 FASEB Science Research Conference focuses on recent advances in our understanding of the regulatory mechanisms controlling normal and abnormal functions of muscle-resident stem cells in regeneration, muscle homeostasis, hypertrophy, aging and muscle degenerative disease.

Eight plenary sessions and three dedicated poster sessions will encompass the following major themes: transcriptional and posttranscriptional regulation of gene expression in stem cells, satellite cell heterogeneity and potential, stem cell signaling and environmental interactions, satellite cell quiescence, activation and renewal, non-satellite stem cells, satellite cell proliferation, commitment and differentiation, muscle stem cells in growth and hypertrophy, and muscle stem cells in aging, disease and therapeutics.

This FASEB Conference increasingly attracts investigators in related fields who are interested in the rapid advances in muscle stem cell research, and interdisciplinary interactions are an important feature of this meeting. Collectively, this conference, which represents the only international conference that focuses exclusively on muscle satellite and stem cell populations, provides a venue to present cutting edge research, foster discussions, and promote collaborative interactions, with the goal of advancing a fundamental understanding of muscle-resident stem cells, and ultimately, translating this knowledge to the clinic.

###

FASEB has announced a total of 35 Science Research Conferences (SRC) in 2014. Registration opens January 17, 2014. For more information about an SRC, view preliminary programs, or find a listing of all our 2014 SRCs, please visit http://www.faseb.org/SRC.

Since 1982, FASEB SRC has offered a continuing series of inter-disciplinary exchanges that are recognized as a valuable complement to the highly successful society meetings. Divided into small groups, scientists from around the world meet intimately and without distractions to explore new approaches to those research areas undergoing rapid scientific changes.

In efforts to expand the SRC series, potential organizers are encouraged to contact SRC staff at SRC@faseb.org. Proposal guidelines can be found at http://www.faseb.org/SRC.

View post:
FASEB announces 2014 Science Research Conference: Skeletal Muscle Satellite and Stem Cells

→←